Anvisa aprova Nexviazyme® (alfa-avalglicosidase) para tratamento de pacientes com Doença de Pompe
Segs,
A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de conceder aprovação regulatória para o medicamento Nexviazyme® (alfa…
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
Overview of attention for article published in Lancet Neurology, December 2021
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (96th percentile)
-
High Attention Score compared to outputs of the same age and source (84th percentile)
Mentioned by
- news
- 2 news outlets
- blogs
- 1 blog
- policy
- 1 policy source
- 20 X users
- patent
- 2 patents
- guideline
- 2 clinical guideline sources
Readers on
- mendeley
- 159 Mendeley
